TERIFLUNOMIDE | A209677 | SOLA PHARMACEUTICALS
| Case | Court | Filed | Status | Judge |
|---|---|---|---|---|
Sanofi-Aventis U.S. LLC et al v. IMPAX Laboratories, Inc. 2 patentsANDA 209677teriflunomide | D. Del. | 2017-01-03 | Terminated 2017-04-21 | — |
Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).
Highest NADAC/Unit
$0.3692
per ea
Lowest NADAC/Unit
$0.3198
per ea
Brand NDCs
0
Generic NDCs
2
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 70512085128TERIFLUNOMIDE 14 MG TABLET | $0.3692 | EA | Generic | — | 2026-06-17 |
| 70512085028TERIFLUNOMIDE 7 MG TABLET | $0.3198 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.